Biobanking remains a hot area of investment with a predicted growth of 30% by 2015. Can you afford to miss out?
With a complex web of technical, legal, ethical and informatic considerations to be taken into account it has never been more crucial to keep ahead in the latest developments in the biobanking field.
We bring together leaders from industry, academia and institutions from across the globe facilitating learning and development to maximise your research opportunities.
Representatives from GlaxoSmithKline, AstraZeneca, Merck, Sanofi-Aventis and many others highlight the newest and most innovative advances in the industry.
Join us in London this October to discuss and learn how to:
- Maximise sample utilisation by developing effective data management: gain insight to the newest developments in informatics from National Institute of Health’s BIOLINK
- Join Amelia Warner (Merck) to increase effectiveness of worldwide sample collection facilitating research into the global market
- Clarify and develop your ethical and legal understanding with presentations from the National Research Ethics Service along side industry and academic case studies from Merck and CESagen
- Overcome the challenges faced in varying samples with case studies from the Brain Bank, Kings College London
- Promote effective medical research by facilitating networking opportunities: a novel approach to networking from Cambridge’s NIHR
2012 provides more networking opportunities than ever before with panel discussions, open forums, round table sessions and an all new crisis management session facilitating the networking between banks.
Come to London this September for a senior level interactive event - giving you the edge in the research world.
Praise for Pharma IQ’s Global Biobanking 2011…
“Much better than similar conferences, a very good representation of Pharmas, much information shared” – Anne Bahr – Sanofi
Biobanking at Roche - Interview with Gerd Maass, VP for R&D at Roche Pharmaceuticals
With a focus on biobanking Maass outlines some common difficulties in isolating biomarkers from samples that have previously been stored in a bio/tissue bank; he shares his opinions on storage techniques for samples to get the best results. He also sheds light on the state of Roche’s internal biobank, discusses the extent to which Roche sources samples externally from biobanks, and the main difficulties/challenges with this. Finally, he gives some research-side advice for new or expanding biobanks.